Published in final edited form as:

Int J Vitam Nutr Res. 2017 May ; 87(3-4): 149–158. doi:10.1024/0300-9831/a000570.

Pomegranate juice and extract extended lifespan and reduced intestinal fat deposition in *Caenorhabditis elegans*

Jolene Zheng^{1,2}, David Heber³, Mingming Wang², Chenfei Gao², Steven B. Heymsfield¹, Roy J. Martin⁴, Frank L. Greenway¹, John W. Finley², Jeffrey H. Burton¹, William D. Johnson¹, Frederick M. Enright⁵, Michael J. Keenan^{1,2}, Zhaoping Li³

¹Pennington Biomedical Research Center, Louisiana State University, Baton Rouge, LA, USA

²School of Nutrition and Food Sciences, Louisiana State University, Baton Rouge, LA, USA

³Department of Medicine, University of California Los Angeles, Los Angeles, CA, USA

⁴Department of Nutrition, University of California, Davis, CA, USA

⁵School of Animal Sciences, Louisiana State University, Baton Rouge, LA, USA

Abstract

Pomegranate juice with a high content of polyphenols, pomegranate extract, ellagic acid, and urolithin A, have anti-oxidant and anti-obesity effects in humans. Pomegranate juice extends lifespan of *Drosophila melanogaster*. *Caenorhabditis elegans* (*C. elegans*) (n = 6) compared to the control group in each treatment, lifespan was increased by pomegranate juice in wild type (N2, 56 %, P < 0.001) and *daf-16* mutant (*daf-16(mgDf50)I*) (18 %, P = 0.00012), by pomegranate extract in N2 (28 %, P = 0.00004) and in *daf-16(mgDf50)I* (10 %, P < 0.05), or by ellagic acid (11 %, P < 0.05). Pomegranate juice reduced intestinal fat deposition (IFD) in *C. elegans* (n = 10) N2 (–68 %, P = 0.0003) or in the *daf-16(mgDf50)I* (–33 %, P = 0.0034). The intestinal fat deposition was increased by pomegranate extract in N2 (137 %, P < 0.0138) and in *daf-16(mgDf50)I* (26 %, P = 0.0225), by ellagic acid in N2 (66 %, P < 0.0001) and in *daf-16(mgDf50)I* (74 %, P < 0.0001), or by urolithin A in N2 (57 %, P = 0.0039) and in *daf-16(mgDf50)I* (43 %, P = 0.0001). These effects were partially mediated by the *daf-16* pathway. The data may offer insights to human aging and obesity due to homology with *C. elegans*.

Jolene Zheng, Pennington Biomedical Research Center, Louisiana State University, 6400 Perkins Road, Baton Rouge, LA, 70808, USA, ccwork2015@outlook.com.

Conflicts of interest

The authors declare that there are no conflicts of interest.

Electronic supplementary material

The electronic supplementary material is available with the online version of the article at <http://dx.doi.org/10.1024/0300-9831/a000xxx>

ESM 1. Figure.

The estimated GAE (gallic acid equivalent, mg/ml) by calculation related to the lifespan extension at lower doses.

ESM 2. Table.

Additional statistics for lifespan (P < 0.05).

ESM 3. Table.

Calculated GAE (gallic acid equivalent) content in the doses of the PJ and POMx (extract of pomegranate juice) used in this study.

ESM 4. Table.

Correlation of estimated GAE with the dose-responses (A-shape).

Keywords

Pomegranate; ellagic acid; urolithin acid; lifespan; fat; *C. elegans*

Introduction

Health determines human lifespan as well as optimal quality of life [1, 2]. Aging at the cellular level involves complex interacting mechanisms that lead to functional decline which become manifest following birth and proceed through life. A U. S. population-based study demonstrated that mortality risk was directly correlated with body mass index (BMI). Thus, above 25 kg/m², BMI inversely correlated with lifespan [3]. The increasing age of western societies creates a greater burden of chronic diseases including cancer, cardiovascular disease, diabetes, and neurodegenerative disorders including Parkinson's disease and Alzheimer's disease [4, 5], leading to a high cost of health care and a great financial burden to the public health system and families [6]. Among complex factors, both obesity and aging decrease insulin sensitivity, impair the immune response, increase inflammation, impair the gut-bloodstream barrier, and decrease physical mobility [7]. Many dietary interventions provide noninvasive approaches to reinforcing optimal nutrition, fighting metabolic dysfunction, enhancing physiological function, and promoting a healthy lifespan [8].

Dietary polyphenol antioxidants play important roles in health [9]. Polyphenols in blueberries extends lifespan in *C. elegans* [10]. Pomegranates (*Punica granatum* L.) juice have a high content of polyphenols. Anthocyanins (387 mg/L), punicalagins (1561 mg/L), ellagic acids (121 mg/L), and other hydrolyzable tannins (417 mg/L) are the major polyphenols in PJ (Pom Wonderful) [11]. Pomegranates consist of about 80 % of juice and 20 % of seeds with water (85 %), and 10 % sugars [12, 13] (Table I). Pomegranate juice (PJ) has been shown to extend lifespan in mice [14, 15] and *Drosophila melanogaster* [16], and fructose demonstrated the similar effects in *C. elegans* in one of our recent studies [17]. PJ has shown effects in controlling the condition of type 2 diabetic patients [18]. Consumption of PJ (1.5 ml per kilograms body weight) reduces the fasting serum glucose and insulin resistance in type 2 diabetic patients significantly [19]. Pomegranate extract (POMx) potentiates lifespan extension with dietary restriction, a finding attributed by polyphenols [14, 15]. POMx and PJ can also act as prebiotics, having demonstrated antibacterial properties *in vitro*, and can block DNA repair and inhibit proliferation of breast cancer cells (MCF-7) *in vitro*, as well as modulate the IGF-IGFBP axis [20, 21]. POMx and PJ down-regulate androgen-synthesizing genes and induce apoptosis in human prostate cells (kappaB-dependent) *in vitro* and in mice *in vivo* [22, 23]. POMx and PJ decrease prostate specific antigen in humans after surgery or radiation [24, 25], inhibit tumor-associated angiogenesis *in vitro* and *in vivo* [26], suppress inflammatory cell signaling in colon cancer cells (50 mg/L PJ, *in vitro*) [27], improve memory [28] and improve fecundity in humans [29].

As the main bioactive component, ellagic acid (EA) is a measure of the quality of products [30]. EA in humans reaches a maximum plasma level in 1 hour (31.9ng/ml), is eliminated within 4 hours [31] and exerts an antioxidant effect [32]. The colonic microflora forms the main active metabolite of EA, urolithin A (UA). UA lasts longer in the body than EA, other

EA metabolites [11, 33], and has better bioavailability [34]. UA also suppresses colorectal, hepatic, and prostate cancers synergistically with EA *in vitro* and in mice *in vivo* [35, 36].

The *C. elegans* model-organism is the first animal model to have its genome completely sequenced. *C. elegans* conserves 65 % of the genes associated with human disease, and has more than 300 transgenic and mutant strains available for use in functional biomedical research [37–45]. The *C. elegans daf-16* gene, a homologue of the human gene FOXO, regulates *C. elegans* lifespan and mediates both lipid metabolism and insulin signaling pathways [46, 47]. Transcriptional factor *skn-1* regulates lifespan in parallel to *daf-16*/FOXO in the *daf-2*-mediated insulin/IGF-1-like signaling pathway and mutation of *skn-1* is sensitive to oxidative stress and has shorter lifespan [48]. Heat shock factor (*hsf-1*) also played important role in the regulation of lifespan by regulating stress-inducible gene expression [49].

We hypothesized that pomegranate would increase lifespan while reducing intestinal fat deposition (IFD). We evaluated four PJ products using the *C. elegans* wild type (N2) to assess their effect on lifespan, IFD using Nile red and to predict their potential effect on aging and obesity in humans. In addition, we also used a *daf-16* deficient mutant to assess the role of the FOXO signaling pathway in mediating the effects of botanicals evaluated.

Materials and Methods

The *Caenorhabditis elegans* model organism is a low cost and convenient model for testing dietary substances. *C. elegans* strains and their standard lab food, *Escherichia coli* (*E. coli*, OP50, Uracil auxotroph), were obtained from the *Caenorhabditis* Genetics Center (University of Minnesota, Minneapolis, MN). PJ was obtained from the first-press squeezing of the whole pomegranate fruit (POM Wonderful® LLC, Los Angeles, CA, USA) (<http://www.pomwonderful.com/pomegranate-products/juice/100-pomegranate-juice/>) and was purchased from a local grocery store. Extraction of the remaining fruit residue obtained after the first pressing for PJ, POMx powder was produced from a solid-phase extraction with a high concentration of polyphenols, a gift from POM Wonderful® LLC (Los Angeles, CA, USA). We obtained EA from Sigma (St. Louis, MO, USA). Dr. David Heber's laboratory synthesized the UA [11, 50].

Culture of *Escherichia coli* (*E. coli*, OP50)

We cultured the standard laboratory food of *C. elegans*, *E. coli* strain (OP50, uracil auxotroph) by the standard method described elsewhere [44, 51, 52]. Briefly, we added approximately 10 µL of stock *E. coli* solution to media and incubated at 37 °C for 24h. The OP50 were then plated in Petrifilm™ (3M Corporate, St. Paul, MN) at 37 °C for 24h until densities of 5×10⁸ to 5×10¹¹ *colony forming units* (cfu/ml) were reached and then were fed to the *C. elegans* ad libitum [44, 53]. We added additional concentrated OP50 to the plate every two weeks to maintain the concentration of OP50. The OP50 stock feeding solution was enriched to 2×10⁹cfu/ml by centrifuging at 2,200 g for 10 Minutes and washed with S-complete buffer [54] twice.

Culture of *C. elegans*

Mature gravid wild type *C. elegans* (N2, Bristol) and *daf-16* deficient mutants [*daf-16(mgDf50)*] were treated with NaOH (1M) and sodium hypochlorite solution (5.25 %, 5:2 ratio) to dissolve the body and release viable eggs [44]. The eggs hatched the next day after washing with S-complete solution 3 times. The age-synchronized *C. elegans* were diluted to 100 animals/ml, plated in liquid culture in a 96 well plate (120µl/well, 10–15 animals) [54] with OP50 (109cfu/ml), and incubated in 20 °C (N2) or 15 °C (*daf-16* mutant) low temperature incubators (Revco Tech., Nashville, NC, USA). We added thirty microliters of 5-Fluoro-2'-deoxyuridine (FUDR, 0.6mM) stock solution to each well at L4 stage. The *C. elegans* model does not require regulation of the Institutional Animal Care and Use Committee (IACUC).

Lifespan assays

We added fifty microliters of the treatments to each well three days after egg-synchronization. The control group received OP50 only. The experimental groups received additional PJ (0.01 %, 0.1 %, 1 %, 3 %, 5 %, 10 % or 25 %, v/v), POMx (5, 10, 20, 40, 80, 160, and 320µg/ml), EA (1, 2, 5, 10, 25, and 50µM in dimethyl sulfoxide (DMSO 0.05 %)), or UA (1, 2, 5, 10, 25, and 50µM in DMSO) (n = 10–15/well/6well). We used a second control (DMSO, 0.05 %) in the EA and UA groups. We manually recorded the numbers of live animals every other day under a microscope (Nikon, Eclipse Ti –S, Japan).

Fluorescence microscopy

We used the lipophilic dye, Nile red, to stain for intestinal fat deposition (IFD), and fluorescent intensity was evaluated [44]. *C. elegans* in each group were collected after 3 days of treatments, washed with S-Basal twice, fixed with paraformaldehyde (4 %) over 2h at 4 °C and washed with PBS for 5 min × 3. Nile red (50 µL) was applied to the specimens for 10 min. Ten microliters of Fluoromount-G (Southern Biotechnology Associates, Birmingham, AL) was applied to a glass slide followed by 10 µL of the medium containing Nile red stained *C. elegans*. A cover glass was mounted on the glass slide, and the slides were viewed with an epifluorescence microscope (Nikon Eclipse, Ti) equipped with a Texas Red filter. We randomly selected ten animal/slides, and took fluorescent micrographs with a digital camera (Andor, DU-885k) and analyzed using Nikon-Elements (version 3.22.11). Optical densities (arbitrary units) of Nile red stained IFD were determined for adult animals (larvae 4).

Statistical Analysis

Analyses were carried out using SAS/STAT® software, Version 9.4 of the SAS System for Windows (Cary, NC, USA). All results were expressed as mean ± S. E.M. Normality and homogeneity of variance of data was checked by Shapiro-Wilk test and HOVTEST. Survival curves were displayed by binomial probabilities obtained from logistic regression models as surrogates for survival probabilities and mean lifespan was estimated via Kaplan-Meier (log-rank). ANOVA models were used to analyze fluorescence intensity data and pairwise differences of least squares means for different doses were compared via two-sample t-tests. Statistical significance was defined as $P < 0.05$.

Results

PJ treatment dose-dependently extended lifespan of N2 up to 56 % or *daf-16* mutant up to 30 % in an A-shape curve, and decreased the magnitude of the lifespan extension at higher doses. A similar trend with half the magnitude was seen in POMx treated animals in N2 (28 %). EA or UA did not significantly affect lifespan overall, however, lifespan extension was observed in several days of the experiment in each treatment (ESM 2). The fluorescent intensity of IFD in *C. elegans* was reduced by PJ in N2 (–68 %) or in *daf-16* (–33 %). In contrast, IFD was increased in N2 more than the *daf-16* mutant by POMx (137 % at 320µg/ml vs. 26 % at 20µg/ml), or UA (57 % at 10µM vs. 43 % at 50µM). IFD was increased by EA in N2 (66 % at 5µM and in *daf-16* mutant (74 % at 25µM).

PJ dose-dependently extended then reduced lifespan in N2 and the *daf-16* mutant

In a dose-dependent manner, PJ added to the cultures significantly increased mean lifespan in N2 up to the 1 % dose but produced reduced lifespans at higher doses, an A-shape curve relationship (Figure 1a & b). The mean lifespan was increased at lower doses (0.1 % – 1 %) from 21 to 33 days (42 %, $P = 0.00642$ & 56 %, $P < 0.001$) while it was decreased at higher doses (10 % & 25 %) from 33 to 4 days (–67 %, $P < 0.001$ & –81 %, $P < 0.001$) (Figure 1b). Similarly, in the *daf-16* mutant, PJ also significantly increased mean lifespan in a dose-dependent manner up to 5 %, but lifespan was significantly reduced at higher doses. The dose-response curve shifted to the right (Figure 1c). The mean lifespan of the *daf-16* mutant was increased from 27 to 32 days at a dose (5 %) that reduced lifespan in N2 (18 %, $P = 0.00012$) and decreased at the higher doses (–61 % at 10 %, $P < 0.001$ & –49 % at 25 %, $P < 0.001$, Figure 1b). Additionally, we observed specific days during the experiment at which significant differences in survival probabilities, which were provided (ESM 2).

PJ dose-dependently reduced the fluorescent intensity of IFD in N2 and the *daf-16* mutant (L4). In N2, the IFD was reduced from 6971 ± 607 to 2372 ± 245 (–30 % at 1 %, $P = 0.0459$, –44 % at 3 %, $P = 0.0052$, –66 % at 5 %, $P = 0.0005$, –68 % at 10 %, $P = 0.0003$ & –55 % at 25 %, $P = 0.0028$, $n = 10$, $P < 0.05$). The IFD was increased at lower doses in the *daf-16* mutant from 4677 ± 136 to 7222 ± 240 (54 % at 0.01 %, $P < 0.0001$ & 28 % at 0.1 %, $P < 0.05$, $n = 10$), followed by reduction at higher doses to 3134 ± 252 (–24 % at 1 %, –21 % at 5 %, $P < 0.05$; & –33 % at 25 %, $n = 10$, $P = 0.0034$) (Figure 1d).

POMx dose-dependently increased

A dose-response curve for lifespan extension was also present in the N2 group treated with POMx, but was absent in the *daf-16* mutant (Figure 2a). The mean lifespan was elevated from 18 to 22 days (18 % at 10µg/ml, $P = 0.00622$ & 28 % at 20µg/ml, $P = 0.00004$, Figure 2b & 2c). The mean lifespan of the *daf-16* mutant was not altered (Figure 2b). Additionally, specific days during the experiment at which significant differences in survival probabilities were observed are provided (ESM 2).

In N2, lower doses of POMx slightly reduced the IFD ($P < 0.05$) followed by an increase from 3323 ± 63 to 7515 ± 125 at the highest dose (137 % at 320µg/ml, $n = 10$, $P < 0.0138$). Similarly in the *daf-16* mutant, POMx increased the IFD from 5012 ± 1032 to 6327 ± 716 at

mid-dose (26 % at 20µg/ml, n = 10, P = 0.0225) followed by a reduction to 3815 ± 736 at a higher dose (23.9 % at 80µg/ml, n = 10, P = 0.0429) (Figure 2d).

EA did not alter lifespan in N2 or in the *daf-16* mutant

Unlike PJ and POMx that increased lifespan dose-dependently, EA did not alter lifespan in N2 or the *daf-16* mutant and the mean lifespan also being unchanged ($P < 0.05$, Figure 3a & 3b). The mean lifespan of the *daf-16* mutant was not significant ($P < 0.05$, Figure 3b & 3c). The specific days during the experiment at which significant differences in survival probabilities were observed are provided (ESM 2). The IFD elevation by EA was dose-dependent, similar in both N2 and the *daf-16* mutant, and in parallel with a 2-fold elevation in the *daf-16* mutant. In N2, EA increased IFD from 5190 ± 158 to 8608 ± 323 at higher doses (66 % at 5µM, 59 % at 10µM, 58 % at 25µM, & 47 % at 50µM, n = 10, $P < 0.0001$). Similarly in the *daf-16* mutant, EA increased IFD at the higher doses from 8237 ± 227 to 14324 ± 113 (60 % at 10µM, 74 % at 25µM, & 49 % at 50µM, n = 10, $P < 0.0001$) (Figure 3d).

UA did not alter lifespan in N2 or in the *daf-16* mutant

As with EA, UA did not alter the lifespan in N2 or the *daf-16* mutant. In N2, the mean lifespan was not changed ($P < 0.05$, Figure 4a & 4b). The mean lifespan of the *daf-16* mutant seemed reduced, but the change was not significant ($P < 0.05$, Figure 4b & 4c). Additionally, during the experiment, significant differences in survival probabilities were observed within two days (ESM 2). IFD was increased in N2, from 1362 ± 61 to 6278 ± 991 in the DMSO-control group (the increase was 361 % at 0.05 % DMSO, n = 10, $P < 0.05$). There was a greater increase to 9860 ± 216 at higher doses (the increase was 57 % at 10µM, $P = 0.0039$, was 47 % at 25µM, $P = 0.0177$ and was 46 % at 50µM, $P = 0.0216$, n = 10). The IFD in the *daf-16* mutant was increased from 3021 ± 127 to 4324 ± 177 dose-dependently (34 % at 10µM, $P = 0.0273$ & 43 % at 50µM, $P = 0.0001$, n = 10) (Figure 4d).

Discussion

Our findings reveal that the lifespan extension has the same trend, on a larger or on a smaller scale, in N2 and the *daf-16* mutant by treatment with PJ or POMx, and has minimal effects on lifespan in cultures treated with EA or UA. These results indicated that the *daf-16* pathway was partially required for lifespan extension in the present study. We approximated the survival curves displayed by estimated probabilities of survival across the lifespan (Binomial). Although some treatment groups show statistically significant differences, one cannot use comparisons based on these probabilities to draw conclusions regarding lifespan.

The maximum lifespan of N2 could be affected by the concentration of OP50 and FUDR and as long as 58 days of lifespan in N2 is observed [55]. In a similar condition, our study recorded the maximum 44 days of lifespan in N2 in control group, while PJ extended the maximum lifespan of N2 to 60 days (Figure 1a).

As energy sources, appropriate amount of sugar should have beneficial effects on lifespan extension. However, high sugar (< 2 %) in the diet is detrimental to the *C. elegans* and reduces lifespan [45, 56]. We saw dose-response curves with an A-shape in PJ and POMx

treated animals, but were puzzled by the fact that the lower doses of PJ increased lifespan, while the higher doses decreased the lifespan. We wondered if the unusual dose-response relationship might be due to PJ's sugar content, since fructose increases lifespan in yeast [58], mosquitoes [59], and nematodes, while decreasing fat deposition (in nematodes) at lower concentrations [17]. We found a reversal of the lifespan extension by PJ at a dose that contained 0.4 % sugar. PJ has a high content of sugars in which the fructose is 1.25-fold greater than that of glucose which, in turn, is 4.7-fold higher than that of mannitol [60]. In agar dish culture, extra glucose (< 0.001 % or 2 %) reduces lifespan mainly due to reducing signals of the *DAF-16*/FOXO and heat shock transcription factor (*HSF-1*) gene signaling [61, 62]. The effect of fructose, however, is controversial. Supplemental fructose reduces the plasma glucose level, glyco-hemoglobin, serum cholesterol, triglycerides, lactate, and body weight in type 2 diabetes [63, 64]. Many epidemiological studies link the consumption of high dietary fructose usage to an increased prevalence of obesity. Since associations do not show cause and effect, we need clinical trials to support this hypothesized cause for obesity [65, 66]. It appears that the A-shape dose-response relationship with the lifespan in the present study relates to the increasing sugar content. On the other hand, the level of sugar tolerance may be specie-dependent, since a diet emended with PJ (10 %) increased the lifespan of flies [16]. Since the reduced lifespan was observed only at the highest dose in the *daf-16* mutant group, the data implies involvement of the *daf-16* pathway. The A-shape curve of PJ showed the longest lifespan to be at a sugar content of 0.13 % in N2 and 0.66 % in the *daf-16* mutant. The fact that PJ increased lifespan of the *daf-16* mutant in our study may indicate alternative mechanism. The lifespan curve shifting rightward might indicate an "independent or compensatory effect of the *daf-16* pathway".

Fat storage is one of the outcomes of energy consumption and energy expenditure in living organisms. In *C. elegans*, the fluorescent intensity of IFD of the PJ group was reduced in both N2 and the *daf-16* mutant. This inverse relationship of lifespan and fat content (PJ 1 %) is in agreement with studies that PJ is effective in reducing cardiovascular risk factors in overweight humans [67].

POMx is characterized by its rich polyphenol content and extended the lifespan in a similar manner to PJ with an A-shape curve in N2. POMx in the *daf-16* mutant extended lifespan by several days (ESM 2). Unlike PJ, POMx did not reduce lifespan at higher doses. One can attribute the results to either an absent or reduced sugar content and/or other unknown factors. The effect of POMx on lifespan extension was only half the magnitude of the lifespan extension induced by PJ, which suggests that multiple factors in the PJ products extend lifespan as was suggested by the Heber's studies [68]. Also unlike PJ, a V-shape dose-response curve was detected for the IFD in POMx treated animals at the doses that were used in this study, and only a minimal reduction of IFD was observed ($P < 0.05$). The reversal of the pattern of increase in lifespan extension and decrease in IFD occurred at 80 mg/ml, which seems to relate to the sugar content as it did in PJ treated group. Elevating IFD in the *daf-16* mutant suggests the involvement of this pathway controlling body fat accumulation.

Unlike either PJ or POMx, EA, at the doses used, did not alter lifespan in N2 or in the *daf-16* mutant. We observed a lifespan extension on several days of the experiment, which

was similar to a study of N2 in agar culture in which the EA (50 μ M at 0.3 % DMSO) prolonged mean lifespan [51].

DMSO is a solvent that extends lifespan dose-dependently in N2 with an “A-shape” curve, in agar culture (24 % at 0.05 % to 5 %, v/v) [69] and in a liquid culture (20 % at 0.9 %, v/v) [70]. In the present study, DMSO doses were limited to the minimum. The lower DMSO dose (0.05 %) extended lifespan up to 12.7 %, while the higher amount (0.1 %) decreased the lifespan which is different from the observations of the Wang group [69], which observed a 30 % reduction in lifespan in the *daf-16* mutant (9.4 %). The effect of EA on extending lifespan suggested complex mechanisms involving *daf-16*, a gene known for lifespan in *C. elegans*. EA also dose-dependently increased IFD at higher doses in N2 with parallel findings in the *daf-16* mutant. The enhanced IFD in the *daf-16* mutant that was not seen in the PJ treated groups uncovered an important role of the *daf-16* in lipid/energy metabolism.

Like all polyphenols, EA's large molecular weight and hydrophilic properties could have limited the absorption in the intestine as well as the bioavailability to the hosts. Since the main metabolites of EA have many beneficial effects, the effects of UA which is a metabolite of the colonic micro-biota that has a higher absorption index has attracted extensive research in recent years [71]. UA has anti-inflammatory, anti-carcinogenic, anti-glycative, anti-oxidant, and anti-microbial effects [71–73]. In our study, some of the treatment groups showed a statistically significant increase in mean survival probabilities in the presence of UA. Although one cannot draw conclusions from these observations, it is possible that higher doses of UA might alter lifespan, and the *daf-16* mutant pathway may mediate the effect of UA on lifespan. UA also dose-dependently increased IFD at higher doses in both N2 and in the *daf-16* mutant, in parallel, with the latter having half the increase in IFD.

The antioxidant potency of PJ is higher (by at least 20 %) compared to other polyphenol-rich products including red wine, Concord grape juice, blueberry juice, black cherry juice, cranberry juice, orange juice, iced tea beverages, and apple juice *in vitro* [74]. Thus, PJ has superior antioxidant bioactivity compared to its purified polyphenols, EA, punicalagin, or total pomegranate tannin. The “A-shaped” dose-response curves demonstrated in this study with PJ seemed similar to a hormesis reaction [57]. The mechanism by which a certain dosage-range achieved an extended lifespan but reversal at a lower or higher dosage was incompletely understood [17]. Ellagitannin comprised 90 % of the tannin polyphenols in the POM products used in this study, but ellagitannin did not extend lifespan suggesting multifactorial effects and chemical synergy of the action of multiple compounds in PJ compared to single purified active ingredients [68].

EA content varies by variety of the fruit, and many commercial pomegranate extracts were found not to contain the same amount of EA [75]. We used a commercially available PJ product, described in a full analysis of 477 commercial PJ in the market across North America and Asia [76]. Although studies in humans the pharmacokinetics of EA and UA that are equivalent [50], our study showed, as previously reported, that PJ was the most potent in extending lifespan and reducing IFD with POMx being only half as potent. The

total phenolic content, by organic phenolic acid gallic acid equivalent (GAE), are 4.7-fold higher in PJ (2,825µg/ml GAE) than in that of POMx (606µg/mg GAE) [20]. In the present study, the estimated GAE (mg/ml) by calculation was also directly related to the lifespan extension at lower doses by PJ or POMx, which was reduced by higher doses (ESM 1, ESM 3, ESM 4). Thus, the fact that PJ was more potent than POMx may be beyond differences amount of polyphenols but the synergy of various components rather than, for example, EA only [77]. The lower or lack of effect of other tested substances compared to PJ suggest that some effective compounds may be reduced or absent, and multifactorial effects were present.

Our data from the *C. elegans* model indicate that the extension of lifespan by pomegranate is partially dependent on the *daf-16* pathway, but mechanisms other than those involving polyphenols such as EA and its metabolites including UA may play a role as well. The unique effects of PJ in reducing IFD suggest that the effects are due to more than one component. The results of the *C. elegans* studies provide useful information and suggest that, at the proper dilution, PJ may have optimal health benefits including control of fat storage, prevent obesity and offer a solution to delay aging in humans.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgements

JZ, ZL, DH, MW and CG contributed to the conception and design of the study; JZ, ZL, DH, MW, CG, FG, JB and WJ contributed to the acquisition and analysis of data; RM, FE, SH, MK contributed to manuscript review and discussion; eve ryone contributed to the drafting or review of the manuscript. The authors would like to thank Dr. Donald Ingram for his thorough and insightful review of this manuscript. The *C. elegans* strains were from the Caenorhabditis Genetics Center, which is funded by the National Center for Research Resources (NCRR) of the NIH. Drs. Burton and Johnson are supported by 1 U54 GM104940 from the National Institute of General Medical Sciences of the National Institutes of Health which funds the Louisiana Clinical and Translational Science Center. This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors. The pomegranate juice used in this study was purchased with personal funds.

References

1. Mattison JA, Roth GS, Beasley TM, Tilmont EM, Handy AM, Herbert RL, Longo DL, Allison DB, Young JE, Bryant M, Barnard D, Ward WF, Qi W, Ingram DK and de Cabo R (2012). Impact of caloric restriction on health and survival in rhesus monkeys from the NIA study. *Nature*, 489, 318–321. [PubMed: 22932268]
2. Roth GS, Mattison JA, Ottinger MA, Chachich ME, Lane MA and Ingram DK (2004). Aging in rhesus monkeys: relevance to human health interventions. *Science*, 305, 1423–1426. [PubMed: 15353793]
3. Finch CE (2007). Chapter 3 – Energy Balance, Inflammation, and Aging In: *The Biology of Human Longevity* (edited by FINCH CE). pp. 175–232. Academic Press, Burlington.
4. Schulz JB and Deuschl G (2015). [Influence of lifestyle on neurodegenerative diseases]. *Nervenarzt*.
5. Kim J, Li Y and Watkins BA (2013). Fat to treat fat: emerging relationship between dietary PUFA, endocannabinoids, and obesity. *Prostaglandins Other Lipid Mediat*, 104–105, 32–41.
6. Maresova P, Klimova B and Kuca K (2015). Alzheimers disease: cost cuts call for novel drugs development and national strategy. *Ceska Slov Farm*, 64, 25–30. [PubMed: 26084646]

7. Padwal RS, Pajewski NM, Allison DB and Sharma AM (2011). Using the Edmonton obesity staging system to predict mortality in a population-representative cohort of people with overweight and obesity. *Cmaj*, 183, E1059–1066. [PubMed: 21844111]
8. Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ and Flegal KM (2006). Prevalence of overweight and obesity in the United States, 1999–2004. *JAMA*, 295, 1549–1555. [PubMed: 16595758]
9. de Camargo AC, Regitano-d'Arce MA, Biasoto AC and Shahidi F (2014). Low molecular weight phenolics of grape juice and winemaking byproducts: antioxidant activities and inhibition of oxidation of human low-density lipoprotein cholesterol and DNA strand breakage. *J Agric Food Chem*, 62, 12159–12171. [PubMed: 25417599]
10. Wilson MA, Shukitt-Hale B, Kalt W, Ingram DK, Joseph JA and Wolkow CA (2006). Blueberry polyphenols increase lifespan and thermotolerance in *Caenorhabditis elegans*. *Aging Cell*, 5, 59–68. [PubMed: 16441844]
11. Seeram NP, Henning SM, Zhang Y, Suchard M, Li Z and Heber D (2006). Pomegranate juice ellagitannin metabolites are present in human plasma and some persist in urine for up to 48 hours. *J Nutr*, 136, 2481–2485. [PubMed: 16988113]
12. Aviram M, Dornfeld L, Rosenblat M, Volkova N, Kaplan M, Coleman R, Hayek T, Presser D and Fuhrman B (2000). Pomegranate juice consumption reduces oxidative stress, atherogenic modifications to LDL, and platelet aggregation: studies in humans and in atherosclerotic apolipoprotein E-deficient mice. *The American journal of clinical nutrition*, 71, 1062–1076. [PubMed: 10799367]
13. Hakkinen IP (1980). The purification procedure for human gastric juice FSA and its chemical composition. *Clin Exp Immunol*, 42, 57–62. [PubMed: 7460391]
14. Aires DJ, Rockwell G, Wang T, Frontera J, Wick J, Wang W, Tonkovic-Capin M, Lu J, E L, Zhu H and Swerdlow RH (2012). Potentiation of dietary restriction-induced lifespan extension by polyphenols. *Biochimica et biophysica acta*, 1822, 522–526. [PubMed: 22265987]
15. Uysal U, Seremet S, Lamping JW, Adams JM, Liu DY, Swerdlow RH and Aires DJ (2013). Consumption of polyphenol plants may slow aging and associated diseases. *Current pharmaceutical design*, 19, 6094–6111. [PubMed: 23448445]
16. Balasubramani SP, Mohan J, Chatterjee A, Patnaik E, Kukkupuni SK, Nongthomba U and Venkatasubramanian P (2014). Pomegranate Juice Enhances Healthy Lifespan in *Drosophila melanogaster*: An Exploratory Study. *Frontiers in public health*, 2, 245. [PubMed: 25566518]
17. Zheng J, Gao C, Wang M, Tran P, Mai N, Finley JW, Heymsfield SB, Greenway FL, Li Z, Heber D, Burton JH, Johnson WD and Laine RA (2017). Lower Doses of Fructose Extend Lifespan in *Caenorhabditis elegans*. *J Diet Suppl*, 14, 264–277. [PubMed: 27680107]
18. Banihani S, Swedan S and Alguraan Z (2013). Pomegranate and type 2 diabetes. *Nutrition research*, 33, 341–348. [PubMed: 23684435]
19. Banihani SA, Makahleh SM, El-Akawi Z, Al-Fashtaki RA, Khabour OF, Gharibeh MY, Saadah NA, Al-Hashimi FH and Al-Khasieb NJ (2014). Fresh pomegranate juice ameliorates insulin resistance, enhances beta-cell function, and decreases fasting serum glucose in type 2 diabetic patients. *Nutrition research*, 34, 862–867. [PubMed: 25223711]
20. Li Z, Summanen PH, Komoriya T, Henning SM, Lee RP, Carlson E, Heber D and Finegold SM (2015). Pomegranate ellagitannins stimulate growth of gut bacteria in vitro: Implications for prebiotic and metabolic effects. *Anaerobe*, 34, 164–168. [PubMed: 26051169]
21. Finegold SM, Summanen PH, Corbett K, Downes J, Henning SM and Li Z (2014). Pomegranate extract exhibits in vitro activity against *Clostridium difficile*. *Nutrition*, 30, 1210–1212. [PubMed: 24976424]
22. Rettig MB, Heber D, An J, Seeram NP, Rao JY, Liu H, Klatte T, Belldgrun A, Moro A, Henning SM, Mo D, Aronson WJ and Pantuck A (2008). Pomegranate extract inhibits androgen-independent prostate cancer growth through a nuclear factor-kappaB-dependent mechanism. *Mol Cancer Ther*, 7, 2662–2671. [PubMed: 18790748]
23. Hong MY, Seeram NP and Heber D (2008). Pomegranate polyphenols down-regulate expression of androgen-synthesizing genes in human prostate cancer cells overexpressing the androgen receptor. *J Nutr Biochem*, 19, 848–855. [PubMed: 18479901]

24. Heber D (2008). Multitargeted therapy of cancer by ellagitannins. *Cancer Lett*, 269, 262–268. [PubMed: 18468784]
25. Pantuck AJ, Leppert JT, Zomorodian N, Aronson W, Hong J, Barnard RJ, Seeram N, Liker H, Wang H, Elashoff R, Heber D, Aviram M, Ignarro L and Beldegrun A (2006). Phase II study of pomegranate juice for men with rising prostate-specific antigen following surgery or radiation for prostate cancer. *Clin Cancer Res*, 12, 4018–4026. [PubMed: 16818701]
26. Sartippour MR, Seeram NP, Rao JY, Moro A, Harris DM, Henning SM, Firouzi A, Rettig MB, Aronson WJ, Pantuck AJ and Heber D (2008). Ellagitannin-rich pomegranate extract inhibits angiogenesis in prostate cancer in vitro and in vivo. *Int J Oncol*, 32, 475–480. [PubMed: 18202771]
27. Adams LS, Seeram NP, Aggarwal BB, Takada Y, Sand D and Heber D (2006). Pomegranate juice, total pomegranate ellagitannins, and punicalagin suppress inflammatory cell signaling in colon cancer cells. *J Agric Food Chem*, 54, 980–985. [PubMed: 16448212]
28. Bookheimer SY, Renner BA, Ekstrom A, Li Z, Henning SM, Brown JA, Jones M, Moody T and Small GW (2013). Pomegranate juice augments memory and FMRI activity in middle-aged and older adults with mild memory complaints. Evidence-based complementary and alternative medicine: eCAM. 2013, 946298. [PubMed: 23970941]
29. Henning SM, Zhang Y, Rontoyanni VG, Huang J, Lee RP, Trang A, Nuernberger G and Heber D (2014). Variability in the antioxidant activity of dietary supplements from pomegranate, milk thistle, green tea, grape seed, goji, and acai: effects of in vitro digestion. *J Agric Food Chem*, 62, 4313–4321. [PubMed: 24745654]
30. Medjakovic S and Jungbauer A (2013). Pomegranate: a fruit that ameliorates metabolic syndrome. *Food Funct*, 4, 19–39. [PubMed: 23060097]
31. Seeram NP, Lee R and Heber D (2004). Bioavailability of ellagic acid in human plasma after consumption of ellagitannins from pomegranate (*Punica granatum L.*) juice. *Clin Chim Acta*, 348, 63–68. [PubMed: 15369737]
32. Heber D, Seeram NP, Wyatt H, Henning SM, Zhang Y, Ogden LG, Dreher M and Hill JO (2007). Safety and antioxidant activity of a pomegranate ellagitannin-enriched polyphenol dietary supplement in overweight individuals with increased waist size. *J Agric Food Chem*, 55, 10050–10054. [PubMed: 17966977]
33. Li Z, Henning SM, Lee RP, Lu QY, Summanen PH, Thames G, Corbett K, Downes J, Tseng CH, Finegold SM and Heber D (2015). Pomegranate extract induces ellagitannin metabolite formation and changes stool microbiota in healthy volunteers. *Food Funct*.
34. Piwowarski JP, Granica S and Kiss AK (2014). Influence of gut microbiota-derived ellagitannins' metabolites urolithins on pro-inflammatory activities of human neutrophils. *Planta Med*, 80, 887–895. [PubMed: 24995502]
35. Sanchez-Gonzalez C, Ciudad CJ, Izquierdo-Pulido M and Noe V (2015). Urolithin A causes p21 up-regulation in prostate cancer cells. *Eur J Nutr*.
36. Cho H, Jung H, Lee H, Yi HC, Kwak HK and Hwang KT (2015). Chemopreventive activity of ellagitannins and their derivatives from black raspberry seeds on HT-29 colon cancer cells. *Food Funct*, 6, 1675–1683. [PubMed: 25906041]
37. Brenner S (1974). The genetics of *Caenorhabditis elegans*. *Genetics*, 77, 71–94. [PubMed: 4366476]
38. Zheng J and Greenway FL (2012). *Caenorhabditis elegans* as a model for obesity research. *Int J Obes (Lond)*. 36, 186–194. [PubMed: 21556043]
39. Wicks SR, Yeh RT, Gish WR, Waterston RH and Plasterk RH (2001). Rapid gene mapping in *Caenorhabditis elegans* using a high density polymorphism map. *Nature genetics*, 28, 160–164. [PubMed: 11381264]
40. Consortium C.e.S.(1998). Genome sequence of the nematode *C. elegans*: a platform for investigating biology. *Science*, 282, 2012–2018. [PubMed: 9851916]
41. Gao C, Gao Z, Greenway FL, Burton JH, Johnson WD, Keenan MJ, Enright FM, Martin RJ, Chu Y and Zheng J (2015). Oat consumption reduced intestinal fat deposition and improved health span in *Caenorhabditis elegans* model. *Nutr Res*.

42. Gao C, King ML, Fitzpatrick ZL, Wei W, King JF, Wang M, Greenway FL, Finley JW, Johnson WD, Keenan MJ, En-right FM, Martin RJ and Zheng J (2015). Prowashonupana barley dietary fibre reduces body fat and increases insulin sensitivity in *Caenorhabditis elegans* model. *Journal of Functional Foods*, 18, 11.
43. Finley JW, Sandlin C, Holiday DL, Keenan MJ, Prinyawiwatkul Wand Zheng J (2013). Legumes reduced intestinal fat deposition in the *Caenorhabditis elegans* model system. *Journal of Functional Foods*, 5, 1487–1493.
44. Zheng J, Enright F, Keenan M, Finley J, Zhou J, Ye J, Greenway F, Senevirathne RN, Gissendanner CR, Manaois R, Prudente A, King JM and Martin R (2010). Resistant starch, fermented resistant starch, and short-chain fatty acids reduce intestinal fat deposition in *Caenorhabditis elegans*. *J Agric Food Chem*, 58, 4744–4748. [PubMed: 20353151]
45. Zheng J, Greenway FL, Heymsfield SB, Johnson WD, King JF, King MJ, Gao C, Chu YF and Finley JW (2014). Effects of three intense sweeteners on fat storage in the *C. elegans* model. *Chemico-biological interactions*. 215, 1–6. [PubMed: 24632416]
46. Lin K, Hsin H, Libina N and Kenyon C (2001). Regulation of the *Caenorhabditis elegans* longevity protein DAF-16 by insulin/IGF-1 and germline signaling. *Nat Genet*, 28, 139–145. [PubMed: 11381260]
47. Ogg S, Paradis S, Gottlieb S, Patterson GI, Lee L, Tissenbaum HA and Ruvkun G (1997). The Fork head transcription factor DAF-16 transduces insulin-like metabolic and longevity signals in *C. elegans*. *Nature*, 389, 994–999. [PubMed: 9353126]
48. An JH and Blackwell TK (2003). SKN-1 links *C. elegans* mesendodermal specification to a conserved oxidative stress response. *Genes & development*. 17, 1882–1893. [PubMed: 12869585]
49. Morley JF and Morimoto RI (2004). Regulation of longevity in *Caenorhabditis elegans* by heat shock factor and molecular chaperones. *Mol Biol Cell*, 15, 657–664. [PubMed: 14668486]
50. Seeram NP, Zhang Y, McKeever R, Henning SM, Lee RP, Suchard MA, Li Z, Chen S, Thames G, Zerlin A, Nguyen M, Wang D, Dreher M and Heber D (2008). Pomegranate juice and extracts provide similar levels of plasma and uri-nary ellagitannin metabolites in human subjects. *J Med Food*, 11, 390–394. [PubMed: 18598186]
51. Saul N, Pietsch K, Sturzenbaum SR, Menzel R and Steinberg CE (2011). Diversity of polyphenol action in *Caenorhabditis elegans*: between toxicity and longevity. *J Nat Prod*, 74, 1713–1720. [PubMed: 21805983]
52. Kilicgun H, Arda N and Ucar EO (2015). Identification of longevity, fertility and growth-promoting properties of pomegranate in *Caenorhabditis elegans*. *Pharmacogn Mag*, 11, 356–359. [PubMed: 25829775]
53. Gruber J, Ng LF, Poovathingal SK and Halliwell B (2009). Deceptively simple but simply deceptive – *Caenorhabditis elegans* lifespan studies: considerations for aging and antioxidant effects. *FEBS Lett*, 583, 3377–3387. [PubMed: 19815017]
54. Solis GM and Petrascheck M (2011). Measuring *Caenorhabditis elegans* life span in 96 well microtiter plates. *Journal of Visualized Experiments*.
55. Win MT, Yamamoto Y, Munesue S, Han D, Harada S and Yamamoto H (2013). Validated Liquid Culture Monitoring System for Lifespan Extension of *Caenorhabditis elegans* through Genetic and Dietary Manipulations. *Aging Dis*, 4, 178–185. [PubMed: 23936742]
56. Liggett MR, Hoy MJ, Mastroianni M and Mondoux MA (2015). High-glucose diets have sex-specific effects on aging in *C. elegans*: toxic to hermaphrodites but beneficial to males. *Aging (Albany NY)*. 7, 383–388. [PubMed: 26143626]
57. Saul N, Pietsch K, Sturzenbaum SR, Menzel R and Steinberg CE (2013). Hormesis and longevity with tannins: free of charge or cost-intensive? *Chemosphere*. 93, 1005–1008. [PubMed: 23876505]
58. Barbieri M, Bonafe M, Franceschi C and Paolisso G (2003). Insulin/IGF-I-signaling pathway: an evolutionarily conserved mechanism of longevity from yeast to humans. *Am J Physiol Endocrinol MeTab*. 285, E1064–1071. [PubMed: 14534077]
59. Kessler S, Vlimant M and Guerin PM (2015). Sugar-sensitive neurone responses and sugar feeding preferences influence lifespan and biting behaviours of the Afrotropical malaria mosquito, *Anopheles gambiae*. *Journal of comparative physiology A, Neuroethology, sensory, neural, and behavioral physiology*. 201, 317–329.

60. Zhang Y, Krueger D, Durst R, Lee R, Wang D, Seeram N and Heber D (2009). International multidimensional authenticity specification (IMAS) algorithm for detection of commercial pomegranate juice adulteration. *J Agric Food Chem*, 57, 2550–2557. [PubMed: 19249817]
61. Choi SS (2011). High glucose diets shorten lifespan of *Caenorhabditis elegans* via ectopic apoptosis induction. *Nutr Res Pract*, 5, 214–218. [PubMed: 21779524]
62. Mondoux MA, Love DC, Ghosh SK, Fukushima T, Bond M, Weerasinghe GR, Hanover JA and Krause MW (2011). O-linked-N-acetylglucosamine cycling and insulin signaling are required for the glucose stress response in *Caenorhabditis elegans*. *Genetics*, 188, 369–382. [PubMed: 21441213]
63. Anderson JW, Story LJ, Zettwoch NC, Gustafson NJ and Jefferson BS (1989). Metabolic effects of fructose supplementation in diabetic individuals. *Diabetes Care*, 12, 337–344. [PubMed: 2721342]
64. Yip I, Go VL, DeShields S, Saltsman P, Bellman M, Thames G, Murray S, Wang HJ, Elashoff R and Heber D (2001). Liquid meal replacements and glycemic control in obese type 2 diabetes patients. *Obes Res*, 9 Suppl 4, 341S–347S. [PubMed: 11707563]
65. White JS (2008). Straight talk about high-fructose corn syrup: what it is and what it ain't. *The American journal of clinical nutrition*, 88, 1716s–1721s. [PubMed: 19064536]
66. Keller A and Bucher Della Torre S (2015). Sugar-Sweetened Beverages and Obesity among Children and Adolescents: A Review of Systematic Literature Reviews. *Child Obes*, 11, 338–346. [PubMed: 26258560]
67. Tsang C, Smail NF, Almoosawi S, Davidson I and Al-Dujaili EA (2012). Intake of polyphenol-rich pomegranate pure juice influences urinary glucocorticoids, blood pressure and homeostasis model assessment of insulin resistance in human volunteers. *J Nutr Sci*, 1, e9. [PubMed: 25191556]
68. Seeram NP, Adams LS, Henning SM, Niu Y, Zhang Y, Nair MG and Heber D (2005). In vitro antiproliferative, apoptotic and antioxidant activities of punicalagin, ellagic acid and a total pomegranate tannin extract are enhanced in combination with other polyphenols as found in pomegranate juice. *J Nutr Biochem*, 16, 360–367. [PubMed: 15936648]
69. Wang X, Wang X, Li L and Wang D (2010). Lifespan extension in *Caenorhabditis elegans* by DMSO is dependent on sir-2.1 and daf-16. *Biochem Biophys Res Commun*, 400, 613–618. [PubMed: 20828537]
70. Frankowski H, Alavez S, Spilman P, Mark KA, Nelson JD, Mollahan P, Rao RV, Chen SF, Lithgow GJ and Ellerby HM (2013). Dimethyl sulfoxide and dimethyl formamide increase lifespan of *C. elegans* in liquid. *Mech Ageing Dev*, 134, 69–78. [PubMed: 23313473]
71. Espin JC, Larrosa M, Garcia-Conesa MT and Tomas-Barberan F (2013). Biological significance of urolithins, the gut microbial ellagic Acid-derived metabolites: the evidence so far. *Evidence-based complementary and alternative medicine : eCAM*. 2013, 270418. [PubMed: 23781257]
72. Heber D (2011). Pomegranate Ellagitannins. In: *Herbal Medicine: Biomolecular and Clinical Aspects* (edited by BENZIE IFF and WACHTEL-GALOR S). Boca Raton (FL).
73. Gimenez-Bastida JA, Larrosa M, Gonzalez-Sarrias A, Tomas-Barberan F, Espin JC and Garcia-Conesa MT (2012). Intestinal ellagitannin metabolites ameliorate cytokine-induced inflammation and associated molecular markers in human colon fibroblasts. *J Agric Food Chem*, 60, 8866–8876. [PubMed: 22463485]
74. Seeram NP, Aviram M, Zhang Y, Henning SM, Feng L, Dreher M and Heber D (2008). Comparison of antioxidant potency of commonly consumed polyphenol-rich beverages in the United States. *J Agric Food Chem*, 56, 1415–1422. [PubMed: 18220345]
75. Zhang Y, Wang D, Lee RP, Henning SM and Heber D (2009). Absence of pomegranate ellagitannins in the majority of commercial Pomegranate extracts: implications for standardization and quality control. *J Agric Food Chem*, 57, 7395–7400. [PubMed: 20349921]
76. Krueger DA (2012). Composition of pomegranate juice. *J AOAC Int*, 95, 163–168. [PubMed: 22468355]
77. Lansky EP (2006). Beware of pomegranates bearing 40 % ellagic Acid. *J Med Food*, 9, 119–122. [PubMed: 16579739]

Figure 1.

PJ dose-dependently increased estimated survival probabilities (displayed by binomial probabilities obtained from logistic regression models as surrogates for survival probabilities, binomial) and mean lifespan (estimated via Kaplan-Meier, log-rank, A-shape) in both N2 (a & b) and *daf-16* mutant (c & b) at lower doses, and dose-dependently reduced it at higher doses (n = 6). PJ dose-dependently reduced the fluorescent intensity of IFD (arbitrary unit) in N2 and *daf-16* mutant (d, n = 10). *P < 0.05 All results were expressed as mean $\pm$ S. E.M.

Figure 2.

An A-shape dose-responses of lifespan extension was present in POMx (extract of pomegranate juice) treated group in both *N2* (a & b) and the *daf-16* mutant (c & b), however, POMx was less potent than PJ. In *N2*, had an initial elevation of life span in the presence of lower doses of POMx which also reduced the IFD (d, $n = 6$). IFD was increase at the highest dose. In the *daf-16* mutant, POMx increased IFD at mid-dose followed by a reduction at a higher dose ($n = 10$). * $P < 0.05$ All results were expressed as mean $\pm$ S. E.M.

Figure 3.

EA did not alter lifespan in *N2* (a & b) but increased the lifespan in the *daf-16* mutant (c & b) at the highest dose ($n = 6$). The IFD (d) was dose-dependently elevated by EA in both *N2* and *daf-16* mutant, and the responses were in parallel with a greater elevation (by 2-fold) in the *daf-16* mutant ($n = 10$). * $P < 0.05$ All results were expressed as mean $\pm$ S. E.M.

Figure 4.

The mean lifespan was increased in *N2* (a & b) but decreased in *daf-16* mutant (c & b) in UA treated group ($n = 6$). Animals treated with UA had an increased IFD (d) in both *N2* and the *daf-16* mutant with a parallel pattern of response with *N2* showing a greater increase than the *daf-16* mutant ($n = 10$). * $P < 0.05$ All results were expressed as mean $\pm$ S. E.M.

Table I.

Phenolic content of pomegranate juice.

Phytochemical Bioactive	PJ (µg/ml)	POMX(µg/ml)	
		Ambient	Control
Ellagic acid (EA)	96.2	6.44+0.06	6.50+0.02
Punicalagins A&B (PA&B)	418.7	7.32 + 0.10	7.47+ 0.13

PJ : Pomegranate juice; POMX :pomegranate extract.